The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases

The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases

Aims: Switching from originator to biosimilar is part of current practice in inflammatory rheumatic musculoskeletal diseases (iRMDs) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondylarthritis (axSpA), with evidences derived from both etanercept (ETN) to SB4-switching ran...

Full description

Bibliographic Details
Main Authors: Cosimo Bruni, Stefano Gentileschi, Giovanni Pacini, Caterina Baldi, Marco Capassoni, Lorenzo Tofani, Marco Bardelli, Laura Cometi, Luca Cantarini, Francesca Nacci, Michele Vietri, Francesca Bartoli, Ginevra Fiori, Bruno Frediani, Marco Matucci-Cerinic
Format: Article
Language:English
Published: SAGE Publishing 2020-10-01
Series:Therapeutic Advances in Musculoskeletal Disease
Online Access:https://doi.org/10.1177/1759720X20964031

Internet

https://doi.org/10.1177/1759720X20964031

Similar Items